奥格列汀:治疗2型糖尿病的新型长效二肽基肽酶4抑制剂

Omarigliptin:a novel long acting dipeptidyl- peptidase 4 inhibitor for treatment of type 2 diabetes mellitus

奥格列汀是新型长效二肽基肽酶4(DPP-4)抑制剂,主要用于2型糖尿病的治疗,已于2015年在日本上市。奥格列汀(25 mg)1周1次给药单用或与其他口服降血糖药联用,均能显著降低糖化血红蛋白、空腹血糖和餐后血糖水平,疗效较好,耐受性高,患者依从性好。重度肾功能不全或终末期肾病患者在使用奥格列汀时需调整给药剂量,而肝功能不全患者无需调整剂量。

Omarigliptin is a novel long acting dipeptidyl-peptidase 4 （DPP-4） inhibitor used for treatingtype 2 diabetes mellitus. It has been approved in Japan in 2015. Omarigliptin （25 rag） used once weekly as monotherapy or combination with other oral antihyperglyeaemics could significantly decrease the levels of glycosylated hemoglobin Ale, fasting blood glucose and postprandial blood glucose with good tolerance and good medication adherence. When omarigliptin used in patients with severe renal impairment or end- stage renal failure, the dosage should be reduced. But when omarigliptin used in patients with hepatic impairment, there is not necessary for dosage adjustment.